BioVaxys Developing DPX to be the Carrier of Choice for mRNA Vaccines, a market projected to grow to USD$48,000,000,000 by 2030*

Stock Information for BioVaxys Technology Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About BioVaxys Technology Corp.

BioVaxys Strengthens Scientific Team with Addition of Former IMV Vice President of R&D
BioVaxys Technology Corp. Closes Debt Settlement Transaction
CSE Bulletin: MOC Eligibility Update
BIOVAXYS ANNOUNCES UPSIZING OF LIFE OFFERING OF UP TO $2M
BIOVAXYS ANNOUNCES CONVERSION OF DEBENTURES
BIOVAXYS ANNOUNCES CONVERSION OF DEBENTURES
BIOVAXYS ANNOUNCES CONVERSION OF DEBENTURES AND GRANT OF STOCK OPTIONS
BioVaxys Licensee SpayVac-for-Wildlife, Inc., Reports Further Positive Single-Dose Efficacy Data for Its Immunocontraceptive Vaccine and Initiation of Regulatory Submission Process

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.